MY194603A - Anti-Complement Factor Bb Antibodies And Uses Thereof - Google Patents
Anti-Complement Factor Bb Antibodies And Uses ThereofInfo
- Publication number
- MY194603A MY194603A MYPI2018001682A MYPI2018001682A MY194603A MY 194603 A MY194603 A MY 194603A MY PI2018001682 A MYPI2018001682 A MY PI2018001682A MY PI2018001682 A MYPI2018001682 A MY PI2018001682A MY 194603 A MY194603 A MY 194603A
- Authority
- MY
- Malaysia
- Prior art keywords
- antibodies
- complement factor
- complement
- present disclosure
- disclosure provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317897P | 2016-04-04 | 2016-04-04 | |
| PCT/US2017/025784 WO2017176651A1 (en) | 2016-04-04 | 2017-04-03 | Anti-complement factor bb antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY194603A true MY194603A (en) | 2022-12-06 |
Family
ID=60000646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2018001682A MY194603A (en) | 2016-04-04 | 2017-04-03 | Anti-Complement Factor Bb Antibodies And Uses Thereof |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10934347B2 (enExample) |
| EP (1) | EP3452510A4 (enExample) |
| JP (4) | JP6967528B2 (enExample) |
| KR (2) | KR20240096672A (enExample) |
| CN (2) | CN116790614A (enExample) |
| AU (2) | AU2017246794B2 (enExample) |
| BR (1) | BR112018070357A2 (enExample) |
| CA (1) | CA3019332A1 (enExample) |
| CL (1) | CL2018002810A1 (enExample) |
| CO (1) | CO2018010827A2 (enExample) |
| CR (1) | CR20180529A (enExample) |
| DO (1) | DOP2018000219A (enExample) |
| EA (1) | EA201892225A1 (enExample) |
| EC (1) | ECSP18082302A (enExample) |
| IL (3) | IL311675A (enExample) |
| MA (1) | MA44878A (enExample) |
| MX (2) | MX2018012176A (enExample) |
| MY (1) | MY194603A (enExample) |
| PE (1) | PE20190209A1 (enExample) |
| PH (1) | PH12018502137A1 (enExample) |
| SG (1) | SG11201808525UA (enExample) |
| TN (1) | TN2018000341A1 (enExample) |
| WO (1) | WO2017176651A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3543257A1 (en) | 2010-07-28 | 2019-09-25 | Gliknik Inc. | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions |
| SI3325011T1 (sl) | 2015-07-24 | 2021-02-26 | Gliknik Inc. | Fuzijski proteini humanih proteinskih fragmentov za tvorbo pravilnih multimeriziranih imunoglobulin FC sestavkov s povečanim vezanjem komplementa |
| WO2017176651A1 (en) | 2016-04-04 | 2017-10-12 | True North Therapeutics, Inc. | Anti-complement factor bb antibodies and uses thereof |
| IL266988B2 (en) * | 2016-12-09 | 2024-11-01 | Gliknik Inc | Methods of treating inflammatory disorders with multivalent fc compounds |
| EP3551647A4 (en) | 2016-12-09 | 2021-01-13 | Gliknik Inc. | MANUFACTURING OPTIMIZATION OF GL-2045, A MULTIMERIZING STRADOMER |
| WO2018136455A1 (en) * | 2017-01-17 | 2018-07-26 | The Texas A&M University System | Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells |
| US11192944B2 (en) | 2017-10-11 | 2021-12-07 | Bioverativ Usa Inc. | Methods of inducing complement activity |
| CN111727243A (zh) | 2017-12-19 | 2020-09-29 | 北卡罗来纳-查佩尔山大学 | 用于跨越血-脑屏障递送病毒载体的方法和组合物 |
| JP2022540768A (ja) * | 2019-06-27 | 2022-09-20 | ヴェルソー セラピューティクス， インコーポレイテッド | 骨髄細胞炎症性表現型を調節するための抗ｃｄ５３組成物及び方法、ならびにその使用 |
| US11820814B2 (en) * | 2019-07-17 | 2023-11-21 | Gemini Therapeutics Sub, Inc. | Factor H potentiating antibodies and uses thereof |
| WO2021167949A1 (en) * | 2020-02-18 | 2021-08-26 | Children's Hospital Medical Center | Compositions and methods for treating liver disease |
| PH12022552558A1 (en) | 2020-04-20 | 2024-04-22 | Genzyme Corp | Humanized anti-complement factor bb antibodies and uses thereof |
| CA3193488A1 (en) | 2020-09-23 | 2022-03-31 | Jason Allan Wiles | Pharmaceutical compounds for the treatment of complement mediated disorders |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4866132A (en) | 1986-04-17 | 1989-09-12 | The Research Foundation Of State University Of New York | Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| US5256334A (en) | 1988-09-08 | 1993-10-26 | The Research Foundation Of The State University Of New York | Homogeneous radiopaque polymer-organobismuth composites |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1993003769A1 (en) | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| JPH08503855A (ja) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | 嚢胞性線維症に対する遺伝子治療 |
| US5346981A (en) | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| ATE304604T1 (de) | 1993-06-24 | 2005-09-15 | Frank L Graham | Adenovirus vektoren für gentherapie |
| DE69434594T2 (de) | 1993-10-25 | 2006-09-21 | Canji, Inc., San Diego | Rekombinante adenoviren-vektor und verfahren zur verwendung |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| DE69526377T2 (de) | 1994-12-09 | 2002-11-07 | Microscience Ltd | Virulenzgene in der VGC2-Region von Salmonella |
| US5939045A (en) | 1994-12-22 | 1999-08-17 | Nissan Chemical Industries, Ltd. | Organic bismuth derivatives for X-ray imaging |
| US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| PT939647E (pt) | 1996-08-27 | 2002-04-29 | Chiron Corp | Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| JP2001525470A (ja) | 1997-12-12 | 2001-12-11 | マクロメド・インコーポレーテッド | タンパク修飾のためのヘテロ官能化星形ポリ（エチレングリコール） |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| EP1713503B1 (en) | 2004-02-10 | 2013-07-31 | The Regents of the University of Colorado, a Body Corporate | Inhibition of factor b, the alternative complement pathway and methods related thereto |
| CN102532321B (zh) | 2004-06-18 | 2018-10-12 | Ambrx公司 | 新颖抗原结合多肽和其用途 |
| US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| PT2500030E (pt) | 2005-11-04 | 2015-09-24 | Genentech Inc | Uso de inibidores da via do complemento para tratar doenças oculares |
| HUE039865T2 (hu) * | 2005-12-20 | 2019-02-28 | Sbi Biotech Co Ltd | Anti-ILT7 antitest |
| WO2007071061A1 (en) * | 2005-12-23 | 2007-06-28 | Viventia Biotech Inc. | Methods for generating and screening fusion protein libraries and uses thereof |
| US8981060B2 (en) * | 2007-08-27 | 2015-03-17 | Novelmed Therapuetics, Inc. | Method of inhibiting complement activation with factor Bb specific antibodies |
| CA2704973A1 (en) * | 2007-11-08 | 2009-05-14 | Genentech, Inc. | Anti-factor b antibodies and their uses |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| CN102348723A (zh) | 2008-12-05 | 2012-02-08 | 安吉奥开米公司 | 肽治疗剂轭合物及其应用 |
| EP2483307A1 (en) | 2009-09-29 | 2012-08-08 | Fraunhofer USA, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
| EP2755688A4 (en) | 2011-10-27 | 2014-08-06 | Nkt Therapeutics Inc | HUMANIZED ANTIBODIES AGAINST INKT |
| RU2014138474A (ru) | 2012-02-24 | 2016-04-10 | СтемСентРкс, Инк. | Новые модуляторы и способы применения |
| JP6244350B2 (ja) * | 2012-04-03 | 2017-12-06 | ノーベルメッド セラピューティクス インコーポレイテッド． | ヒト化およびキメラ抗因子Ｂｂ抗体、ならびにその使用 |
| WO2014044793A2 (en) * | 2012-09-20 | 2014-03-27 | Max-Delbrück-Centrum für Molekulare Medizin | Cd22-binding peptides |
| PL2914291T3 (pl) * | 2012-11-02 | 2022-10-03 | Bioverativ Usa Inc. | Przeciwciała anty-C1s dopełniacza i ich zastosowania |
| MX2015010682A (es) | 2013-02-22 | 2016-05-31 | Stemcentrx Inc | Nuevos conjugados de anticuerpos y usos de los mismos. |
| US9260527B2 (en) * | 2013-03-15 | 2016-02-16 | Sdix, Llc | Anti-human CXCR4 antibodies and methods of making same |
| US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| KR20160126054A (ko) | 2014-02-27 | 2016-11-01 | 알러간, 인코포레이티드 | 보체 인자 Bb 항체 |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| WO2017176651A1 (en) | 2016-04-04 | 2017-10-12 | True North Therapeutics, Inc. | Anti-complement factor bb antibodies and uses thereof |
| US11192944B2 (en) | 2017-10-11 | 2021-12-07 | Bioverativ Usa Inc. | Methods of inducing complement activity |
| PH12022552558A1 (en) | 2020-04-20 | 2024-04-22 | Genzyme Corp | Humanized anti-complement factor bb antibodies and uses thereof |
-
2017
- 2017-04-03 WO PCT/US2017/025784 patent/WO2017176651A1/en not_active Ceased
- 2017-04-03 BR BR112018070357-5A patent/BR112018070357A2/pt active Search and Examination
- 2017-04-03 MY MYPI2018001682A patent/MY194603A/en unknown
- 2017-04-03 EP EP17779607.5A patent/EP3452510A4/en active Pending
- 2017-04-03 CN CN202210862505.3A patent/CN116790614A/zh active Pending
- 2017-04-03 KR KR1020247018546A patent/KR20240096672A/ko active Pending
- 2017-04-03 IL IL311675A patent/IL311675A/en unknown
- 2017-04-03 JP JP2018552076A patent/JP6967528B2/ja active Active
- 2017-04-03 SG SG11201808525UA patent/SG11201808525UA/en unknown
- 2017-04-03 PE PE2018001946A patent/PE20190209A1/es unknown
- 2017-04-03 MX MX2018012176A patent/MX2018012176A/es unknown
- 2017-04-03 AU AU2017246794A patent/AU2017246794B2/en active Active
- 2017-04-03 CA CA3019332A patent/CA3019332A1/en active Pending
- 2017-04-03 KR KR1020187031483A patent/KR102673420B1/ko active Active
- 2017-04-03 EA EA201892225A patent/EA201892225A1/ru unknown
- 2017-04-03 MA MA044878A patent/MA44878A/fr unknown
- 2017-04-03 CR CR20180529A patent/CR20180529A/es unknown
- 2017-04-03 US US16/091,447 patent/US10934347B2/en active Active
- 2017-04-03 IL IL295288A patent/IL295288B2/en unknown
- 2017-04-03 TN TNP/2018/000341A patent/TN2018000341A1/en unknown
- 2017-04-03 IL IL262010A patent/IL262010B/en unknown
- 2017-04-03 CN CN201780029742.9A patent/CN109563158B/zh active Active
-
2018
- 2018-10-03 CL CL2018002810A patent/CL2018002810A1/es unknown
- 2018-10-04 DO DO2018000219A patent/DOP2018000219A/es unknown
- 2018-10-04 MX MX2023007149A patent/MX2023007149A/es unknown
- 2018-10-04 PH PH12018502137A patent/PH12018502137A1/en unknown
- 2018-10-09 CO CONC2018/0010827A patent/CO2018010827A2/es unknown
- 2018-10-31 EC ECSENADI201882302A patent/ECSP18082302A/es unknown
-
2021
- 2021-01-19 US US17/151,860 patent/US11851482B2/en active Active
- 2021-09-10 JP JP2021147485A patent/JP7326393B2/ja active Active
-
2023
- 2023-08-02 JP JP2023126155A patent/JP2023139289A/ja active Pending
- 2023-11-08 US US18/504,416 patent/US20240228599A1/en active Pending
-
2024
- 2024-09-30 AU AU2024224000A patent/AU2024224000A1/en active Pending
-
2025
- 2025-11-14 JP JP2025194917A patent/JP2026069789A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502137A1 (en) | Anti-complement factor bb antibodies and uses thereof | |
| PH12019502283A1 (en) | Anti-lag3 antibodies | |
| SA519402400B1 (ar) | تركيبات وطرق لعلاج أمراض الهيموجلوبين | |
| MX2019007021A (es) | Anticuerpos il-11ra. | |
| PH12019501357A1 (en) | Anti-ox40 antibodies and their uses | |
| MX2019007020A (es) | Anticuerpos il-11. | |
| MY195442A (en) | Anti-CD40 Antibodies and Their Uses | |
| MY203971A (en) | Anti-lag-3 antibodies and compositions | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| JOP20200074A1 (ar) | أجسام مضادة ضد tau واستخداماتها | |
| MX2017016169A (es) | Anticuerpos anti-her2 y metodos de uso. | |
| MY186334A (en) | Anti-her2 antibodies and immunoconjugates | |
| PH12020551710A1 (en) | Anti-hla-g antibodies and use thereof | |
| EP4335874A3 (en) | Anti-hla-g antibodies and use thereof | |
| MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
| MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
| MY205672A (en) | Anti-phf-tau antibodies and uses thereof | |
| MY191581A (en) | Anti-pd-1 antibodies | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| SG10201803042PA (en) | Anti-tim-3 antibodies | |
| CR20230163A (es) | ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271) | |
| PH12019501872A1 (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
| MX2018004674A (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| MY205689A (en) | Antibody molecules to cd138 and uses thereof |